Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Position Statement

Standards of Medical Care in Diabetes—2011

  1. American Diabetes Association
Diabetes Care 2011 Jan; 34(Supplement 1): S11-S61. https://doi.org/10.2337/dc11-S011
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Tables

  • Table 1

    ADA evidence grading system for clinical practice recommendations

    Level of evidenceDescription
    AClear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered, including:
    • Evidence from a well-conducted multicenter trial

    • Evidence from a meta-analysis that incorporated quality ratings in the analysis

    Compelling nonexperimental evidence, i.e., “all or none” rule developed by Center for Evidence Based Medicine at Oxford
    Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including:
    • Evidence from a well-conducted trial at one or more institutions

    • Evidence from a meta-analysis that incorporated quality ratings in the analysis

    BSupportive evidence from well-conducted cohort studies
    • Evidence from a well-conducted prospective cohort study or registry

    • Evidence from a well-conducted meta-analysis of cohort studies

    Supportive evidence from a well-conducted case-control study
    CSupportive evidence from poorly controlled or uncontrolled studies
    • Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results

    • Evidence from observational studies with high potential for bias (such as case series with comparison to historical controls)

    • Evidence from case series or case reports

    Conflicting evidence with the weight of evidence supporting the recommendation
    EExpert consensus or clinical experience
  • Table 2

    Criteria for the diagnosis of diabetes

    A1C ≥6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.*
    or
    FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.*
    or
    2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.*
    or
    In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dl (11.1 mmol/l)
    • ↵*In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.

  • Table 3

    Categories of increased risk for diabetes (prediabetes)*

    FPG 100–125 mg/dl (5.6–6.9 mmol/l): IFG
    or
    2-h plasma glucose in the 75-g OGTT 140–199 mg/dl (7.8–11.0 mmol/l): IGT
    or
    A1C 5.7–6.4%
    • ↵*For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at higher ends of the range.

  • Table 4

    Criteria for testing for diabetes in asymptomatic adult individuals

    1. Testing should be considered in all adults who are overweight (BMI ≥25 kg/m2*) and have additional risk factors:

      • physical inactivity

      • first-degree relative with diabetes

      • high-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander)

      • women who delivered a baby weighing >9 lb or were diagnosed with GDM

      • hypertension (≥140/90 mmHg or on therapy for hypertension)

      • HDL cholesterol level <35 mg/dl (0.90 mmol/l) and/or a triglyceride level >250 mg/dl (2.82 mmol/l)

      • women with polycystic ovarian syndrome (PCOS)

      • A1C ≥5.7%, IGT, or IFG on previous testing

      • other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans)

      • history of CVD

    2. In the absence of the above criteria, testing for diabetes should begin at age 45 years.

    3. If results are normal, testing should be repeated at least at 3-year intervals, with consideration of more frequent testing depending on initial results and risk status.

    • ↵*At-risk BMI may be lower in some ethnic groups.

  • Table 5

    Testing for type 2 diabetes in asymptomatic children

    Criteria
    • Overweight (BMI >85th percentile for age and sex, weight for height >85th percentile, or weight >120% of ideal for height)

    Plus any two of the following risk factors:
    • Family history of type 2 diabetes in first- or second-degree relative

    • Race/ethnicity (Native American, African American, Latino, Asian American, Pacific Islander)

    • Signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, PCOS, or small-for-gestational-age birth weight)

    • Maternal history of diabetes or GDM during the child's gestation

    Age of initiation: age 10 years or at onset of puberty, if puberty occurs at a younger age
    Frequency: every 3 years
  • Table 6

    Screening for and diagnosis of GDM

    Perform a 75-g OGTT, with plasma glucose measurement fasting and at 1 and 2 h, at 24–28 weeks of gestation in women not previously diagnosed with overt diabetes.
    The OGTT should be performed in the morning after an overnight fast of at least 8 h.
    The diagnosis of GDM is made when any of the following plasma glucose values are exceeded:
    • Fasting ≥92 mg/dl (5.1 mmol/l)

    • 1 h ≥180 mg/dl (10.0 mmol/l)

    • 2 h ≥153 mg/dl (8.5 mmol/l)

  • Table 7

    Therapies proven effective in diabetes prevention trials

    Study (ref.)nPopulationMean age (years)Duration (years)Intervention (daily dose)Incidence in control subjects (%/year)Relative risk reduction (%) (95% CI)3-Year number needed to treatδ
    Lifestyle
        Finnish DPS (14)522IGT, BMI ≥25 kg/m2553.2I-D&E658 (30–70)8.5
        DPP (13)2,161*IGT, BMI ≥24 kg/m2, FPG >5.3 mmol/l513I-D&E10.458 (48–66)6.9
        Da Qing (15)259*IGT (randomized groups)456G-D&E14.538 (14–56)7.9
        Toranomon Study (35)458IGT (men), BMI = 24 kg/m2∼554I-D&E2.467 (P < 0.043)†20.6
        Indian DPP (19)269*IGT462.5I-D&E2329 (21–37)6.4
    Medications
        DPP (13)2,155*IGT, BMI >24 kg/m2, FPG >5.3 mmol/l512.8Metformin (1,700 mg)10.431 (17–43)13.9
        Indian DPP (19)269*IGT462.5Metformin (500 mg)2326 (19–35)6.9
        STOP-NIDDM (17)1,419IGT, FPG >5.6 mmol/l543.2Acarbose (300 mg)12.425 (10–37)9.6
        XENDOS (36)3,277BMI >30 kg/m2434Orlistat (360 mg)2.437 (14–54)45.5
        DREAM (18)5,269IGT or IFG553.0Rosiglitazone (8 mg)9.160 (54–65)6.9
        Voglibose Ph-3 (37)1,780IGT563.0 (1-year Rx)Vogliobose (0.2 mg)12.040 (18–57)21 (1-year Rx)
    • Modified and reprinted with permission (38).

    • ↵Percentage points: δNumber needed to treat to prevent 1 case of diabetes, standardized for a 3-year period to improve comparisons across studies.

    • ↵*Number of participants in the indicated comparisons, not necessarily in entire study.

    • ↵†Calculated from information in the article. DPP, Diabetes Prevention Program; DPS, Diabetes Prevention Study; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; STOP-NIDDM, Study to Prevent Non-Insulin Dependent Diabetes; XENDOS, Xenical in the prevention of Diabetes in Obese Subjects. I, individual; G, group; D&E, diet and exercise.

  • Table 8

    Components of the comprehensive diabetes evaluation

    Medical history
    • Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic laboratory finding)

    • Eating patterns, physical activity habits, nutritional status, and weight history; growth and development in children and adolescents

    • Diabetes education history

    • Review of previous treatment regimens and response to therapy (A1C records)

    • Current treatment of diabetes, including medications, meal plan, physical activity patterns, and results of glucose monitoring and patient's use of data

    • DKA frequency, severity, and cause

    • Hypoglycemic episodes

      • Hypoglycemia awareness

      • Any severe hypoglycemia: frequency and cause

    • History of diabetes-related complications

      • Microvascular: retinopathy, nephropathy, neuropathy (sensory, including history of foot lesions; autonomic, including sexual dysfunction and gastroparesis)

      • Macrovascular: CHD, cerebrovascular disease, PAD

      • Other: psychosocial problems*, dental disease*

    Physical examination
    • Height, weight, BMI

    • Blood pressure determination, including orthostatic measurements when indicated

    • Fundoscopic examination*

    • Thyroid palpation

    • Skin examination (for acanthosis nigricans and insulin injection sites)

    • Comprehensive foot examination:

      • Inspection

      • Palpation of dorsalis pedis and posterior tibial pulses

      • Presence/absence of patellar and Achilles reflexes

      • Determination of proprioception, vibration, and monofilament sensation

    Laboratory evaluation
    • A1C, if results not available within past 2–3 months

    • If not performed/available within past year:

      • Fasting lipid profile, including total, LDL and HDL cholesterol and triglycerides

      • Liver function tests

      • Test for urine albumin excretion with spot urine albumin-to-creatinine ratio

      • Serum creatinine and calculated GFR

      • Thyroid-stimulating hormone in type 1 diabetes, dyslipidemia, or women over age 50 years

    Referrals
    • Annual dilated eye exam

    • Family planning for women of reproductive age

    • Registered dietitian for MNT

    • DSME

    • Dental examination

    • Mental health professional, if needed

    • ↵*See appropriate referrals for these categories.

  • Table 9

    Correlation of A1C with average glucose

    A1C (%)Mean plasma glucose
    mg/dlmmol/l
    61267.0
    71548.6
    818310.2
    921211.8
    1024013.4
    1126914.9
    1229816.5
    • These estimates are based on ADAG data of ∼2,700 glucose measurements over 3 months per A1C measurement in 507 adults with type 1, type 2, and no diabetes. The correlation between A1C and average glucose was 0.92 (51). A calculator for converting A1C results into estimated average glucose (eAG), in either mg/dl or mmol/l, is available at http://professional.diabetes.org/eAG.

  • Table 10

    Summary of glycemic recommendations for many nonpregnant adults with diabetes

    A1C<7.0%*
    Preprandial capillary plasma glucose70–130 mg/dl* (3.9–7.2 mmol/l)
    Peak postprandial capillary plasma glucose†
    • Goals should be individualized based on*:

      • duration of diabetes

      • age/life expectancy

      • comorbid conditions

      • known CVD or advanced microvascular complications

      • hypoglycemia unawareness

      • individual patient considerations

    • More or less stringent glycemic goals may be appropriate for individual patients.

    • Postprandial glucose may be targeted if A1C goals are not met despite reaching preprandial glucose goals.

    <180 mg/dl* (<10.0 mmol/l)
    • Postprandial glucose measurements should be made 1–2 h after the beginning of the meal, generally peak levels in patients with diabetes.

  • Table 11

    Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)

    Study (ref.)CVDStatin dose and comparatorRisk reduction (%)Relative risk reduction (%)Absolute risk reduction (%)LDL cholesterol reduction (mg/dl)LDL cholesterol reduction (%)
    4S-DM (215)2°Simvastatin 20–40 mg vs. placebo85.7 to 43.25042.5186 to 11936
    ASPEN 2° (220)2°Atorvastatin 10 mg vs. placebo39.5 to 24.53415112 to 7929
    HPS-DM (216)2°Simvastatin 40 mg vs. placebo43.8 to 36.3177.5123 to 8431
    CARE-DM (217)2°Pravastatin 40 mg vs. placebo40.8 to 35.4135.4136 to 9927
    TNT-DM (218)2°Atorvastatin 80 mg vs. 10 mg26.3 to 21.6184.799 to 7722
    HPS-DM (216)1°Simvastatin 40 mg vs. placebo17.5 to 11.5346.0124 to 8631
    CARDS (221)1°Atorvastatin 10 mg vs. placebo11.5 to 7.5354118 to 7140
    ASPEN 1° (220)1°Atorvastatin 10 mg vs. placebo9.8 to 7.9191.9114 to 8030
    ASCOT-DM (219)1°Atorvastatin 10 mg vs. placebo11.1 to 10.280.9125 to 8234
    • Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and nonfatal MI. In this tabulation, results of the statin on 10-year risk of major CVD endpoints (CHD death/nonfatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, PharmD, Oregon Health & Science University, 2007.

  • Table 12

    Summary of recommendations for glycemic blood pressure and lipid control for most adults with diabetes

    A1C<7.0%*
    Blood pressure<130/80 mmHg†
    Lipids
        LDL cholesterol<100 mg/dl (<2.6 mmol/l)‡
    • ↵*More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on: duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

    • ↵†Based on patient characteristics and response to therapy, higher or lower systolic blood pressure targets may be appropriate.

    • ↵‡In individuals with overt CVD, a lower LDL cholesterol goal of <70 mg/dl (1.8 mmol/l), using a high dose of a statin, is an option.

  • Table 13

    Definitions of abnormalities in albumin excretion

    CategorySpot collection (μg/mg creatinine)
    Normal<30
    Microalbuminuria30–299
    Macro (clinical)-albuminuria≥300
  • Table 14

    Stages of CKD

    StageDescriptionGFR (ml/min per 1.73 m2 body surface area)
    1Kidney damage* with normal or increased GFR≥90
    2Kidney damage* with mildly decreased GFR60–89
    3Moderately decreased GFR30–59
    4Severely decreased GFR15–29
    5Kidney failure<15 or dialysis
    • ↵*Kidney damage defined as abnormalities on pathologic, urine, blood, or imaging tests. Adapted from ref. 284.

  • Table 15

    Management of CKD in diabetes

    GFR (ml/min/1.73 m2)Recommended
    All patientsYearly measurement of creatinine, urinary albumin excretion, potassium
    45–60Referral to nephrology if possibility for nondiabetic kidney disease exists (duration type 1 diabetes <10 years, heavy proteinuria, abnormal findings on renal ultrasound, resistant hypertension, rapid fall in GFR, or active urinary sediment)
    Consider need for dose adjustment of medications
    Monitor eGFR every 6 months
    Monitor electrolytes, bicarbonate, hemoglobin, calcium, phosphorus, parathyroid hormone at least yearly
    Assure vitamin D sufficiency
    Consider bone density testing
    Referral for dietary counselling
    30–44Monitor eGFR every 3 months
    Monitor electrolytes, bicarbonate, calcium, phosphorus, parathyroid hormone, hemoglobin, albumin, weight every 3–6 months
    Consider need for dose adjustment of medications
    <30Referral to nephrologist
    • Adapted from http://www.kidney.org/professionals/KDOQI/guideline_diabetes/.

  • Table 16

    Plasma blood glucose and A1C goals for type 1 diabetes by age-group

    Plasma blood glucose goal range (mg/dl)A1C (%)Rationale
    Before mealsBedtime/overnight
    Toddlers and preschoolers (0–6 years)100–180110–200<8.5
    • Vulnerability to hypoglycemia

    • Insulin sensitivity

    • Unpredictability in dietary intake and physical activity

    • A lower goal (<8.0%) is reasonable if it can be achieved without excessive hypoglycemia

    School age (6–12 years)90–180100–180<8
    • Vulnerability to hypoglycemia

    • A lower goal (<7.5%) is reasonable if it can be achieved without excessive hypoglycemia

    Adolescents and young adults (13–19 years)90–13090–150<7.5
    • A lower goal (<7.0%) is reasonable if it can be achieved without excessive hypoglycemia

    Key concepts in setting glycemic goals
    • Goals should be individualized and lower goals may be reasonable based on benefit-risk assessment.

    • Blood glucose goals should be modified in children with frequent hypoglycemia or hypoglycemia unawareness.

    • Postprandial blood glucose values should be measured when there is a discrepancy between pre-prandial blood glucose values and A1C levels and to help assess glycemia in those on basal/bolus regimens.

PreviousNext
Back to top
Diabetes Care: 34 (Supplement 1)

In this Issue

January 2011, 34(Supplement 1)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Standards of Medical Care in Diabetes—2011
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Standards of Medical Care in Diabetes—2011
American Diabetes Association
Diabetes Care Jan 2011, 34 (Supplement 1) S11-S61; DOI: 10.2337/dc11-S011

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Standards of Medical Care in Diabetes—2011
American Diabetes Association
Diabetes Care Jan 2011, 34 (Supplement 1) S11-S61; DOI: 10.2337/dc11-S011
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • CONTENTS
    • I. CLASSIFICATION AND DIAGNOSIS OF DIABETES
    • II. TESTING FOR DIABETES IN ASYMPTOMATIC PATIENTS
    • III. DETECTION AND DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS
    • IV. PREVENTION/DELAY OF TYPE 2 DIABETES
    • V. DIABETES CARE
    • VI. PREVENTION AND MANAGEMENT OF DIABETES COMPLICATIONS
    • VII. DIABETES CARE IN SPECIFIC POPULATIONS
    • VIII. DIABETES CARE IN SPECIFIC SETTINGS
    • IX. STRATEGIES FOR IMPROVING DIABETES CARE
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association
  • Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association
  • Diabetes and Hypertension: A Position Statement by the American Diabetes Association
Show more Position Statement

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.